Navigation Links
Finding the Achilles' Heel of ovarian tumor growth
Date:6/19/2014

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors to a protein called focal adhesion kinase (FAK) selectively prevent the growth of ovarian cancer cells as tumor spheroids.

The findings come in a pair of studies published online this week in the journals Gynecologic Oncology and Molecular Cancer Therapeutics.

Ovarian cancer is a leading cause of female cancer death in the United States. On average, more than 21,000 women are diagnosed with ovarian cancer each year and 14,270 die. Many women achieve remission, but cancer recurrence rates exceed 75 percent, prompting the need for new treatments.

"Ovarian cancer spreads within a women's peritoneal space through a unique mechanism that involves the survival of small clusters of tumor cells termed spheroids," said Schlaepfer. "Our studies show that FAK signaling functions at the center of a tumor cell survival signaling network."

In the first study, published in Gynecologic Oncology, first author Nina Shah, MD, a gynecological oncology fellow in the Department of Reproductive Medicine, found that ovarian tumor cells with low levels of a tumor suppressor protein, called merlin, displayed heightened sensitivity to FAK inhibitor growth cessation.

"With FAK inhibitor clinical trials already testing a similar linkage in mesothelioma (a rare cancer that affects the protective lining of many internal organs), our results support the hypothesis that protein biomarkers such as merlin may identify those patients who may best respond to FAK inhibitor therapy," said Schlaepfer.

In the second study in Molecular Cancer Therapeutics, first author Isabelle Tancioni PhD, an assistant project scientist at UC San Diego Moores Cancer Center discovered that a network of signals generated by osteopontin a beta-5 integrin receptor used in cell-to-cell signaling and FAK control ovarian cancer spheroid growth. High levels of beta-5 integrin and FAK expression are associated with a poor prognosis for some ovarian cancer patients. "Thus, high levels of beta-5 integrin may serve as a novel biomarker for ovarian carcinoma cells that possess active FAK signaling," said Schlaepfer.

Schlaepfer noted that tumor recurrence and metastasis are responsible for the majority of ovarian cancer-related deaths and said the new findings support ongoing clinical trials of FAK inhibitors as new agents in the fight to prevent ovarian cancer progression.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. New findings in breast cancer
2. Kessler Foundation scientists present cognitive research findings at MS dual symposium
3. Researchers present new findings for novel pancreatic cancer vaccine
4. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
5. Finding ways to feed pigs for less
6. Once-Banned Bird Flu Study Yields Sobering Findings
7. Columbus Allergist Dr. Summit Shah Discusses Recent Findings on Food Allergies and Exercise-Induced Anaphylaxis
8. Finding brings scientists 1 step closer to Parkinsons drug
9. Relief for Migraine Sufferers as The Life House Offers New Findings, Free Consults
10. New findings by GW researcher break tanning misconceptions: There is no such thing as a safe tan
11. MRI findings shed light on multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding the Achilles' Heel of ovarian tumor growth
(Date:5/24/2017)... Linda, Ca (PRWEB) , ... May 24, 2017 ... ... between effects and background. Understanind and choosing the most appropriate instruments for research ... prove critical in research finding. This webinar will focus on innovations in stereo ...
(Date:5/24/2017)... ... 2017 , ... Altec Products, Inc., a leader in enterprise document ... technology conference in San Diego, CA. , At nVerge 2017, Altec will be ... and enhance their Sage ERP solutions by providing improved visibility and control to the ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Bayside, NY, who have now spent 10 years as clinical instructors for the ... (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Patients who want ... OH, can now meet with Dr. Joseph Bedich for a consultation, with or without ... improving their oral health and functionality. , Dr. Bedich offers a variety ...
(Date:5/24/2017)... Mississippi (PRWEB) , ... May 24, 2017 , ... Myers ... is his has the ability to sell luxury homes anywhere on the planet. The ... the county side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it is ... and STI Technologies Limited to lower diabetes healthcare costs ... STI,s innoviCares card, which is available throughout all provinces ... customers will be eligible for additional savings when shopping ...
(Date:5/3/2017)... 3, 2017  Kalorama Information notes that transplant ... next year and this is projected to continue ... cell (HSCT) or bone marrow transplants require histocompatibility ... well-suited for this task. This according to a ... Information. The various PCR-based methodologies, Sanger sequencing and ...
Breaking Medicine Technology: